Skip to main content

Table 1 Clinicopathological characteristics

From: ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis

Metastatic recurrence cohort (n = 62)n (%)
Age, mean (range)46 (31–80)
Subtypes at primary diagnosis
 ER+/HER2−38 (61%)
 ER+/HER2+13 (21%)
 ER+/HER2 unknown11 (18%)
T stage at primary diagnosis
 T0 - DCIS2 (3%)
 T112 (20%)
 T233 (53%)
 T37 (11%)
 T43 (5%)
 NA5 (8%)
LN+ at primary diagnosis
 Negative10 (16%)
 Positive44 (71%)
 NA8 (13%)
Chemotherapy for primary breast cancer
 Adjuvant24 (38%)
 Neoadjuvant26 (42%)
Endocrine treatments
 Neoadjuvant2 (3%)
 Adjuvant TAM only47 (76%)
 Adjuvant AI/AI + TAM14 (23%)
 Advanced TAM only3 (5%)
 Advanced AI/AI + TAM23 (37%)
Median follow-up from primary diagnosis, median years (range)9.4 (3.3–27.7)
Median follow-up from metastasis, years (range)3.9 (0.1–15.5)